GeneDx Holdings Corp. (NASDAQ:WGS) Position Lifted by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL boosted its holdings in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 67.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 101,810 shares of the company's stock after acquiring an additional 41,084 shares during the period. Tudor Investment Corp ET AL owned 0.37% of GeneDx worth $7,825,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the business. MCF Advisors LLC lifted its position in shares of GeneDx by 107.7% in the fourth quarter. MCF Advisors LLC now owns 351 shares of the company's stock valued at $27,000 after acquiring an additional 182 shares in the last quarter. Sterling Capital Management LLC lifted its holdings in GeneDx by 877.8% in the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company's stock valued at $27,000 after purchasing an additional 316 shares in the last quarter. Global Retirement Partners LLC acquired a new stake in shares of GeneDx during the 4th quarter worth about $28,000. Quarry LP purchased a new stake in shares of GeneDx during the fourth quarter worth about $78,000. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of GeneDx in the fourth quarter valued at approximately $200,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. TD Cowen raised their target price on shares of GeneDx from $75.00 to $118.00 and gave the stock a "buy" rating in a research report on Tuesday, January 7th. Wells Fargo & Company decreased their price objective on GeneDx from $105.00 to $78.00 and set an "equal weight" rating on the stock in a report on Thursday. The Goldman Sachs Group upped their target price on GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a research note on Wednesday, February 19th. Finally, TD Securities decreased their price target on GeneDx from $135.00 to $110.00 and set a "buy" rating on the stock in a research note on Thursday. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $78.14.

Insider Buying and Selling at GeneDx

In other GeneDx news, CEO Katherine Stueland sold 1,078 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $89.44, for a total value of $96,416.32. Following the transaction, the chief executive officer now owns 6,674 shares in the company, valued at $596,922.56. The trade was a 13.91 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Kevin Feeley sold 922 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $94.72, for a total value of $87,331.84. Following the sale, the chief financial officer now owns 5,446 shares of the company's stock, valued at $515,845.12. This represents a 14.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 139,390 shares of company stock valued at $13,043,288 over the last three months. 27.30% of the stock is owned by company insiders.

GeneDx Trading Up 7.9 %

NASDAQ:WGS traded up $4.91 on Friday, hitting $67.23. 2,456,763 shares of the stock were exchanged, compared to its average volume of 717,912. The stock has a market cap of $1.89 billion, a PE ratio of -34.30 and a beta of 1.93. GeneDx Holdings Corp. has a fifty-two week low of $18.80 and a fifty-two week high of $117.75. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. The stock has a fifty day moving average of $94.30 and a 200-day moving average of $82.57.

GeneDx (NASDAQ:WGS - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported $0.28 earnings per share for the quarter, beating analysts' consensus estimates of $0.11 by $0.17. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. The firm had revenue of $87.12 million for the quarter, compared to analysts' expectations of $79.90 million. As a group, equities analysts expect that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.